Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to food. By activating GLP-1 receptors in the pancreas, these substances enhance insulin production and reduce glucagon sec

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing differences in their